Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

327 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Systolic blood pressure reduction during the first 24 h in acute heart failure admission: friend or foe?
Cotter G, Metra M, Davison BA, Jondeau G, Cleland JGF, Bourge RC, Milo O, O'Connor CM, Parker JD, Torre-Amione G, van Veldhuisen DJ, Kobrin I, Rainisio M, Senger S, Edwards C, McMurray JJV, Teerlink JR; VERITAS Investigators. Cotter G, et al. Eur J Heart Fail. 2018 Feb;20(2):317-322. doi: 10.1002/ejhf.889. Epub 2017 Sep 4. Eur J Heart Fail. 2018. PMID: 28871621 Free article. Clinical Trial.
Tezosentan (an intravenous endothelin receptor A/B antagonist) reduces peripheral resistance and increases cardiac power therefore preventing a steep decrease in blood pressure in patients with congestive heart failure.
Cotter G, Kiowski W, Kaluski E, Kobrin I, Milovanov O, Marmor A, Jafari J, Reisin L, Krakover R, Vered Z, Caspi A. Cotter G, et al. Eur J Heart Fail. 2001 Aug;3(4):457-61. doi: 10.1016/s1388-9842(01)00168-4. Eur J Heart Fail. 2001. PMID: 11511432 Free article. Clinical Trial.
RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study.
Kaluski E, Kobrin I, Zimlichman R, Marmor A, Krakov O, Milo O, Frey A, Kaplan S, Krakover R, Caspi A, Vered Z, Cotter G. Kaluski E, et al. Among authors: cotter g. J Am Coll Cardiol. 2003 Jan 15;41(2):204-10. doi: 10.1016/s0735-1097(02)02708-0. J Am Coll Cardiol. 2003. PMID: 12535809 Free article. Clinical Trial.
Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure.
Torre-Amione G, Young JB, Colucci WS, Lewis BS, Pratt C, Cotter G, Stangl K, Elkayam U, Teerlink JR, Frey A, Rainisio M, Kobrin I. Torre-Amione G, et al. Among authors: cotter g. J Am Coll Cardiol. 2003 Jul 2;42(1):140-7. doi: 10.1016/s0735-1097(03)00556-4. J Am Coll Cardiol. 2003. PMID: 12849674 Free article. Clinical Trial.
327 results